Premium
Brexpiprazole shows efficacy in treating acute exacerbation of schizophrenia
Publication year - 2015
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30065
Subject(s) - exacerbation , schizophrenia (object oriented programming) , medicine , placebo , pharmacology , drug , dopamine , psychiatry , anesthesia , alternative medicine , pathology
The serotonin‐dopamine activity modulator brexpiprazole showed significant improvement over placebo in alleviating symptoms in patients with an acute exacerbation of schizophrenia, according to a new study. Daily doses of 2 and 4 mg of the drug each generated statistically significant effects, while a dose of 0.25 mg produced little effect on outcomes. Study results were published online April 16 in the American Journal of Psychiatry .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom